INTRODUCTION

Thrombosis, as one of the risk factors of cardiovascular disease, is the formation of a blood clot in an artery or a vein which starts with platelet aggregation [1,2]. Deep vein thrombosis (DVT) refers to the formation of one or more blood clots in one of the major blood vessels of the body, most commonly in the lower limbs. The most serious complication that can arise from DVT is a pulmonary embolism (PE), which occurs in more than one-third of patients with DVT and often causes sudden death [3-5]. Acetylsalicylic acid (ASA), commonly known as aspirin, is often used as a platelet aggregation inhibitor agent. ASA inhibits platelet aggregation by inhibiting the cyclo-oxygenase (COX) enzyme within the COX pathway, thus preventing thrombus formation [6].

In addition to chemical drugs, herbal medicines have been studied for their potentials as the antithrombotic agent. *Tamarindus indica* L., a flowering plant within the family Fabaceae, is a potential antithrombotic agent due to its active compound dotriacontanoic acid [7]. This compound is one component of D-003, a natural compound comprising triacontanoic, dotriacontanoic, and tetradecanoic acid [8,9]. Experiments with D-003 have demonstrated that this compound can reduce the formation of venous thrombus at a dose of 400 mg/kg [10].

Total flavonoid and phenolic content assays

Total flavonoid content was measured using the aluminum chloride colorimetry method, with absorbance measured at λ=510 nm [10]. The total phenolic compound content was measured using the Folin–Ciocalteu method, with absorbance measured at λ=725 nm [11].

Materials

Ethanol TIE was obtained from the Indonesian Spice and Medicinal Materials and Technologies in Medicine and Dentistry Symposium (PTMDS), Universitas Indonesia. Depok, Indonesia

**ABSTRACT**

Objective: This study aimed to investigate the antithrombotic activity of *Tamarindus indica* L. extract (TIE) in mouse models (*in vivo*).

Methods: TIE was orally administered to mice at three different doses for 7 days. TIE-treated mice were used in two experiments of antithrombotic activity: An examination of bleeding time following tail cutting and an examination of survival rate after collagen-epinephrine-induced thromboembolism. The TIE groups were observed after 7 days of treatment and compared to an aspirin-treated group and a control group.

Results: Treatment with TIE led to a significant increase in bleeding time compared with that in the control group. TIE treatment also protected mice from thromboembolic death, significantly increasing survival rates in a dose-dependent manner.

Conclusion: TIE has the potential as an antithrombotic agent against platelet thromboembolism.

Keywords: Antithrombotic, Bleeding time, Survival rate, *Tamarindus indica* L.
Table 1: Treatment groups used for tests of bleeding time in mice

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of mice (n)</th>
<th>Dosage (mg/20 g mice)</th>
<th>Bleeding time treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASA</td>
<td>5</td>
<td>0.208</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Dose 1</td>
<td>5</td>
<td>14</td>
<td>Tamarind extract (TIE)</td>
</tr>
<tr>
<td>Dose 2</td>
<td>5</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Dose 3</td>
<td>5</td>
<td>56</td>
<td></td>
</tr>
</tbody>
</table>

CMC: Carboxymethyl cellulose, ASA: Acetylsalicylic acid

Table 2: Treatment of survival rate in mice

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of mice (n)</th>
<th>Dosage (mg/20 g mice)</th>
<th>Survival rate treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASA</td>
<td>5</td>
<td>0.208</td>
<td>Saline injection</td>
</tr>
<tr>
<td>Dose 1</td>
<td>5</td>
<td>14</td>
<td>Aspirin</td>
</tr>
<tr>
<td>Dose 2</td>
<td>5</td>
<td>28</td>
<td>Tamarind extract (TIE)</td>
</tr>
<tr>
<td>Dose 3</td>
<td>5</td>
<td>56</td>
<td></td>
</tr>
</tbody>
</table>

CMC: Carboxymethyl cellulose, ASA: Acetylsalicylic acid

in the vein of the tail [12,15]. Control mice were administered an injection of an isotonic saline solution. After 15 min, the number of dead or paralyzed mice was recorded and the survival rate was calculated as follows:

\[
\text{Survival rate} = \left(1 - \frac{\text{number of dead or paralyzed mice}}{\text{total number of mice}}\right) \times 100
\]

The increase in survival rate with TIE treatment was analyzed by comparing the survival rates of each experimental dosage group to that of the vehicle group [12].

Statistical analyses
Analyses were performed using the statistical software SPSS (v.18). Homogeneity of the data was tested using the Levene method and normality was confirmed using the Shapiro–Wilk method. Normally distributed and homogeneous data were analyzed using one-way ANOVAs to assess the overall differences among experimental groups. Pairwise differences between groups were then examined using least significant difference analysis.

RESULTS AND DISCUSSION

Total flavonoid and phenolic content assays
The TIE had a low flavonoid content of 0.002% with no detectable phenolic content.

Bleeding time
Compared to the vehicle group, mice treated with single oral doses of TIE exhibited significantly increased bleeding times (p≤0.05). The experimental group treated with the lowest TIE dose (14 mg/20 g mice) exhibited a 99% increase in bleeding time compared to the vehicle group. Mice treated with higher TIE doses (28 and 56 mg/20 g mice) exhibited increases in bleeding time of 118% and 128%, respectively, compared to the vehicle group. The effects of TIE treatments were qualitatively similar to the effect of the ASA treatment, which resulted in a 125% increase in bleeding time compared to the vehicle group (Fig. 1). The increased bleeding times associated with the ASA and TIE groups provide evidence of the antithrombotic effect of these treatments. Results of the bleeding time tests are shown in Table 3.

Survival rate
TIE-treated experimental group had increased the survival rate in mice. TIE had the same result with ASA from 100% induction of collagen-epinephrine inhibited at doses 2 and 3. The survival rate calculation results were shown in Table 4.

Discussion

Analysis of total flavonoid and phenolic content
Tamarind extract has a low flavonoid content. The sample used in this study had no detectable phenolic content. Flavonoid compounds play a role as antioxidants and also function as antithrombotic agents by reducing adenosine diphosphate (ADP)-induced aggregation and thrombin. Specifically, flavonoids act as TxA2 receptor antagonists, reducing TxA2 which then indirectly inhibits COX-1. In addition, flavonoid compounds increase the production of nitric oxide, which is important for the inhibition of platelet aggregation [16].

Analysis of bleeding time
The antithrombotic effect of TIE was evaluated by comparing the bleeding time of treated animals to animals in the vehicle group. Treatments with TIE, which contains the D-003 compound dotriacontanoic acid, resulted in significant, dose-dependent increases in bleeding time. However, the bleeding times of the TIE-treated animals were not significantly different from those of ASA-treated animals, indicating that the antithrombotic effect was the same for both groups. The largest bleeding time effect was seen in the experimental group given the highest dose of TIE (56 mg/20 g mice).

Inhibition of platelet aggregation includes the reduction of TxA2 formation and prostacyclin (PgI2) enhancement. TxA2 is a potent agonist causing the activation of platelets and thrombus formation. TxA2 causes irreversible platelet aggregation, vasoconstriction, and proliferation of smooth muscle cells [17]. PgI2 is synthesized by PgI2-synthase in endothelial cells and has an effect as an aggregation inhibitor and vasodilator. PgI2 acts to inhibit vasoconstriction and dilate blood vessels [8]. When the formation of the thrombus is inhibited, blood flow is smooth and bleeding times increase.

In this study, the antithrombotic effects of TIE treatments were similar to that of the aspirin treatment. Aspirin inhibits collagen-induced platelet aggregation at optimal doses of 81–162 mg/day [18]. Aspirin works as an antithrombotic agent by inhibiting the enzyme COX and non-COX inhibition. Inhibition of COX-1 will inhibit TxA2 formation and stimulate platelet aggregation. In non-COX enzymes, aspirin will alter glycoprotein IIb/IIIa receptor function and affect the permeability of clots. In addition, aspirin also inhibits acetylcholine, prothrombin, antithrombin, fibrinogen, and factor XIII [18].
Fig. 1: The proportional increase in bleeding time across experimental treatment groups, as compared with the normal control group.

Table 3: Results of bleeding time tests

<table>
<thead>
<tr>
<th>Group</th>
<th>Bleeding time (mean±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>7.32±1.10</td>
</tr>
<tr>
<td>ASA</td>
<td>16.50±3.24*</td>
</tr>
<tr>
<td>Dose 1</td>
<td>14.56±3.02*</td>
</tr>
<tr>
<td>Dose 2</td>
<td>15.92±2.01*</td>
</tr>
<tr>
<td>Dose 3</td>
<td>16.68±3.21*</td>
</tr>
</tbody>
</table>

Normal (CMC 0.5% volume: 0.3 ml/20 g BW), ASA (aspirin 0.208 mg/20 g BW), Dose 1 (14 mg/20 g BW), Dose 2 (28 mg/20 g BW), Dose 3 (56 mg/20 g BW). *p<0.05, compared with the normal control group.

CMC: Carboxymethyl cellulose, ASA: Acetylsalicylic acid, BW: Bodyweight, SD: Standard deviation

Table 4: Survival rates within experimental treatment groups

<table>
<thead>
<tr>
<th>Group</th>
<th>Survival rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>0</td>
</tr>
<tr>
<td>ASA</td>
<td>100</td>
</tr>
<tr>
<td>Dose 1</td>
<td>80</td>
</tr>
<tr>
<td>Dose 2</td>
<td>100</td>
</tr>
<tr>
<td>Dose 3</td>
<td>100</td>
</tr>
</tbody>
</table>

Normal (CMC 0.5% volume: 0.3 ml/20 g BW), ASA (aspirin 0.208 mg/20 g BW), Dose 1 (14 mg/20 g BW), Dose 2 (28 mg/20 g BW), Dose 3 (56 mg/20 g BW).

CMC: Carboxymethyl cellulose, ASA: Acetylsalicylic acid, BW: Bodyweight, TIE: Tamarindus indica L. extract

Analysis of survival rate

A combination of collagen and epinephrine was used to induce thrombosis in the experimental animals. Collagen is a major activator of platelet aggregation induced by ADP. Epinephrine is an $\beta$-adrenergic agonist which causes a disruption of the exchange between potassium ions and sodium and calcium ions, leading to hypokalemia. Hypokalemia causes stimulation of the muscle membrane to be disrupted which can lead to paralysis. The injections of collagen and epinephrine caused the deadly effects in mice through thromboembolism or vasoconstriction by increased $\text{TxA}_2$ and $\text{PGF}_2\alpha$ from platelets.

The active antithrombotic compound within TIE, the D-003 compound dotriacontanoic acid, can inhibit platelet aggregation induced by collagen-epinephrine. The D-003 compound inhibits platelet aggregation induced by collagen, arachidonic acid, serotonin, and ADP [23,24]. In addition, the D-003 compound also inhibits platelet aggregation induced by a combination of collagen and epinephrine [8]. Prior studies have found that treatment with D-003 inhibits platelet aggregation by 55% at a dose of 400 mg/kg BW of mice [8]. The dotriacontanoic acid compound (D-003) can also significantly increase the survival rate in a dose-dependent manner. TIE is more effective at inhibiting platelet aggregation induced by collagen-epinephrine than aggregation that is induced by ADP. A prior study, involving treatment with the D-003 compound at a dose of 200 mg/kg BW of mice, documented that D-003 resulted in a 33% inhibition of ADP-induced platelet aggregation and a 39% inhibition of aggregation induced by collagen-epinephrine [8].

CONCLUSION

Using in vivo experiments, we demonstrated that TIE has antithrombotic potency evidenced by increasing bleeding times and survival rates in TIE-treated experimental animals. The greatest antithrombotic potency was found at a dose of 56 mg/20 g mice.

ACKNOWLEDGMENT

This research was supported by Faculty of Pharmacy, Universitas Indonesia, and funded by Directorate of Research and Community Engagement (PTITTA grant 2018), Universitas Indonesia.

CONFLICTS OF INTEREST

All authors have none to declare.

REFERENCES


